Physician profile
John C Huffman
NPI 1063461523
$3,953.17
in general payments reported to CMS, 2019-2025
24 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $253 · 2021: $562 · 2022: $337 · 2023: $632 · 2024: $644 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,494.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,632.73 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $447.61 | 2023-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $205.88 | 2023-2025 | Syfovre |
| Aerie Pharmaceuticals, INC. | $189.87 | 2019-2021 | |
| Alcon Vision LLC | $156.34 | 2019-2025 | Rocklatan |
| Oyster Point Pharma, INC. | $150.63 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Biotissue Holdings INC. | $136.07 | 2025 | |
| Johnson & Johnson Vision Care, INC. | $132.89 | 2019-2025 | Acuvue |
| Sun Pharmaceutical Industries INC. | $125.00 | 2019-2022 | |
| Astellas Pharma US INC | $115.90 | 2025 | Izervay |
| Bausch & Lomb Americas INC. | $114.42 | 2022-2025 | Vyzulta, Miebo, Zylet |
| Abbvie INC. | $85.29 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $77.93 | 2019 | |
| Coopervision INC. | $64.18 | 2023-2025 | Myday Contact Lens |
| Glaukos Corporation | $64.16 | 2024-2025 | Idose, Istent Infinite |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $61.25 | 2024 | Purified Cortrophin Gel |
| Tarsus Pharmaceuticals, INC. | $40.74 | 2025 | Xdemvy |
| Thea Pharma INC. | $39.85 | 2025 | Iyuzeh |
| Genentech, INC. | $24.39 | 2024 | Vabysmo |
| Sandoz INC. | $22.78 | 2024 | Cimerli |
| Eyepoint US, INC. | $19.14 | 2023 | |
| Akorn, INC. | $17.10 | 2020 | |
| Quidel Corporation | $16.79 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $12.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Huffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.